sarepta therapeutics fda

Order byBest matchMost fresh

Sarepta Will Resume Gene Therapy Shipments

Sarepta Soars After FDA Says Some Patients Can Get Elevidys

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

· 19h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

· 22h

FDA allows Sarepta to resume some Elevidys shipments

· 5h

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

Shares of Sarepta surged Tuesday, a day after the FDA said the company could lift a voluntary pause on shipments of its Elevidys drug, which had been linked to three patient deaths this year.

· 9h

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

· 22h

Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys

· 11h

Sarepta's FDA woes raise questions for future of gene therapy treatments

While Sarepta’s challenges could push some away from investing in gene therapies, it could also lead to interest in different approaches.

· 20h

FDA recommends lifting voluntary hold on Elevidys in ambulatory patients

· 1d

Parents call on FDA for path forward after Duchenne's gene therapy pause | Morning in America

1hon MSN

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doctors to feel safe using it.

6hon MSN

Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially double from current levels to around $40

STAT6h

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and president

1don MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an 8-year-old boy who received Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy. Two other boys have died in recent months after taking the medicine.